Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Metab ; 78: 101822, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37838014

ABSTRACT

OBJECTIVE: Pro-inflammatory polarization of adipose tissue macrophages (ATMs) plays a critical role in the pathogenesis of obesity-associated chronic inflammation. However, little is known about the role of lipids in the regulation of ATMs polarity and inflammation in response to metabolic stress. Deletion of α/ß-hydrolase domain-containing 6 (ABHD6), a monoacylglycerol (MAG) hydrolase, has been shown to protect against diet-induced obesity and insulin resistance. METHODS: Here we investigated the immunometabolic role of macrophage ABHD6 in response to nutrient excess using whole-body ABHD6-KO mice and human and murine macrophage cell-lines treated with KT203, a selective and potent pharmacological ABHD6 inhibitor. RESULTS: KO mice on high-fat diet showed lower susceptibility to systemic diet-induced inflammation. Moreover, in the setting of overnutrition, stromal vascular cells from gonadal fat of KO vs. control mice contained lower number of M1 macrophages and exhibited enhanced levels of metabolically activated macrophages (MMe) and M2 markers, oxygen consumption, and interleukin-6 (IL-6) release. Likewise, under in vitro nutri-stress condition, inhibition of ABHD6 in MMe-polarized macrophages attenuated the expression and release of pro-inflammatory cytokines and M1 markers and induced the upregulation of lipid metabolism genes. ABHD6-inhibited MMe macrophages showed elevated levels of peroxisome proliferator-activated receptors (PPARs) and 2-MAG species. Notably, among different MAG species, only 2-MAG treatment led to increased levels of PPAR target genes in MMe macrophages. CONCLUSIONS: Collectively, our findings identify ABHD6 as a key component of pro-inflammatory macrophage activation in response to excess nutrition and implicate an endogenous macrophage lipolysis/ABHD6/2-MAG/PPARs cascade, as a lipid signaling and immunometabolic pathway, which favors the anti-inflammatory polarization of ATMs in obesity.


Subject(s)
Monoglycerides , Peroxisome Proliferator-Activated Receptors , Humans , Animals , Mice , Peroxisome Proliferator-Activated Receptors/metabolism , Monoglycerides/metabolism , Mice, Obese , Hydrolases/genetics , Hydrolases/metabolism , Adipose Tissue/metabolism , Macrophages/metabolism , Obesity/metabolism , Inflammation/metabolism , Anti-Inflammatory Agents , Diet, High-Fat/adverse effects , Monoacylglycerol Lipases/genetics , Monoacylglycerol Lipases/metabolism
2.
Ultrason Sonochem ; 54: 302-310, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30712858

ABSTRACT

Pollutants of emerging concern contaminate surface and ground water. Advanced oxidation processes treat these molecules and degrade them into smaller compounds or mineralization products. However, little information on coupled advanced oxidation techniques and on the degradation pathways of these pollutants is available to identify possible ecotoxic subproducts. In the present work, we investigate the ultrasound assisted photocatalytic degradation pathway of the herbicide Isoproturon. We worked in batch mode in a thermostatic glass reactor. We compared the activity of nanometric TiO2 P25 with that of Kronos 1077, a micrometric TiO2. We discuss the individual, additive and synergistic degradation action of photolysis, sonolysis, sonophotolysis, and sonophotocatalysis by varying catalyst loading and/or ultrasound power for the last three techniques. With 0.1 g L-1 catalyst, photocatalysis and sonophotopcatalysis completely degrade Isoproturon within 240 min and 60 min, respectively (>99% conversion). Sonophotocatalysis breaks Isoproturon down into smaller molecules than photocatalysis alone.

3.
Diabetologia ; 52(6): 1122-32, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19294363

ABSTRACT

AIMS/HYPOTHESIS: The Zucker fatty (ZF) rat subjected to 60% pancreatectomy (Px) develops moderate diabetes by 3 weeks. We determined whether a progressive fall in beta cell mass and/or beta cell dysfunction contribute to beta cell failure in this type 2 diabetes model. METHODS: Partial (60%) or sham Px was performed in ZF and Zucker lean (ZL) rats. At 3 weeks post-surgery, beta cell mass and proliferation, proinsulin biosynthesis, pancreatic insulin content, insulin secretion, and islet glucose and lipid metabolism were measured. RESULTS: ZL-Px rats maintained normal glycaemia and glucose-stimulated insulin secretion (GSIS) despite incomplete recovery of beta cell mass possibly due to compensatory enhanced islet glucose metabolism and lipolysis. ZF-Px rats developed moderate hyperglycaemia (14 mmol/l), hypertriacylglycerolaemia and relative hypoinsulinaemia. Despite beta cell mass recovery and normal arginine-induced insulin secretion, GSIS and pancreatic insulin content were profoundly lowered in ZF-Px rats. Proinsulin biosynthesis was not reduced. Compensatory increases in islet glucose metabolism above those observed in ZF-Sham rats were not seen in ZF-Px rats. Triacylglycerol content was not increased in ZF-Px islets, possibly due to lipodetoxification by enhanced lipolysis and fatty acid oxidation. Fatty acid accumulation into monoacylglycerol and diacylglycerol was increased in ZF-Px islets together with a 4.5-fold elevation in stearoyl-CoA desaturase mRNA expression. CONCLUSIONS/INTERPRETATION: Falling beta cell mass, reduced proinsulin biosynthesis and islet steatosis are not implicated in early beta cell failure and glucolipotoxicity in ZF-Px rats. Rather, severe beta cell dysfunction with a specific reduction in GSIS and marked depletion of beta cell insulin stores with altered lipid partitioning underlie beta cell failure in this animal model of type 2 diabetes.


Subject(s)
Hyperlipidemias/metabolism , Hyperlipidemias/pathology , Insulin-Secreting Cells/pathology , Islets of Langerhans/pathology , Obesity/metabolism , Obesity/pathology , Animals , Body Weight , Cell Proliferation , Cells, Cultured , Fatty Acids, Nonesterified/metabolism , Hyperlipidemias/physiopathology , Immunohistochemistry , Insulin/metabolism , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/metabolism , Lipid Metabolism/physiology , Male , Obesity/physiopathology , Pancreatectomy , Proinsulin/metabolism , Rats , Rats, Zucker
4.
Diabetologia ; 49(9): 2120-30, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16868750

ABSTRACT

AIMS/HYPOTHESIS: The aim of this study was to determine the role of fatty acid signalling in islet beta cell compensation for insulin resistance in the Zucker fatty fa/fa (ZF) rat, a genetic model of severe obesity, hyperlipidaemia and insulin resistance that does not develop diabetes. MATERIALS AND METHODS: NEFA augmentation of insulin secretion and fatty acid metabolism were studied in isolated islets from ZF and Zucker lean (ZL) control rats. RESULTS: Exogenous palmitate markedly potentiated glucose-stimulated insulin secretion (GSIS) in ZF islets, allowing robust secretion at physiological glucose levels (5-8 mmol/l). Exogenous palmitate also synergised with glucagon-like peptide-1 and the cyclic AMP-raising agent forskolin to enhance GSIS in ZF islets only. In assessing islet fatty acid metabolism, we found increased glucose-responsive palmitate esterification and lipolysis processes in ZF islets, suggestive of enhanced triglyceride-fatty acid cycling. Interruption of glucose-stimulated lipolysis by the lipase inhibitor Orlistat (tetrahydrolipstatin) blunted palmitate-augmented GSIS in ZF islets. Fatty acid oxidation was also higher at intermediate glucose levels in ZF islets and steatotic triglyceride accumulation was absent. CONCLUSIONS/INTERPRETATION: The results highlight the potential importance of NEFA and glucoincretin enhancement of insulin secretion in beta cell compensation for insulin resistance. We propose that coordinated glucose-responsive fatty acid esterification and lipolysis processes, suggestive of triglyceride-fatty acid cycling, play a role in the coupling mechanisms of glucose-induced insulin secretion as well as in beta cell compensation and the hypersecretion of insulin in obesity.


Subject(s)
Insulin Resistance , Insulin-Secreting Cells/metabolism , Insulin/metabolism , Islets of Langerhans/metabolism , Animals , Binding Sites , Colforsin/pharmacology , Fatty Acids, Nonesterified/metabolism , Fatty Acids, Nonesterified/pharmacology , Gene Expression Regulation/drug effects , Glucagon-Like Peptide 1/pharmacology , Glucose/pharmacology , In Vitro Techniques , Insulin Secretion , Insulin-Secreting Cells/drug effects , Islets of Langerhans/cytology , Islets of Langerhans/drug effects , Lactones/metabolism , Lactones/pharmacology , Lipase/metabolism , Lipid Metabolism/drug effects , Lipolysis/drug effects , Models, Biological , Orlistat , Oxidation-Reduction/drug effects , Rats , Rats, Zucker , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects
5.
Circ Res ; 86(1): 76-85, 2000.
Article in English | MEDLINE | ID: mdl-10625308

ABSTRACT

Apoptosis of arterial smooth muscle cells (ASMCs) could play an important role in the pathogenesis of atherosclerosis and restenosis. Recent studies have demonstrated that extracellular adenosine induces apoptosis in various cell types. Our aim was to delineate the capacity of this nucleoside to induce ASMC apoptosis in arterial diseases. We demonstrate that adenosine dose-dependently triggers apoptosis of cultured human ASMCs. Apoptotic cell death was quantified by analysis of nuclear chromatin morphology and characterized by DNA laddering. The involvement of adenosine receptors was suggested, because neither an adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride, nor an inhibitor of cellular nucleoside transport, dipyridamole, was able to inhibit adenosine-induced ASMC apoptosis. In contrast, an A(1)/A(2)-adenosine receptor antagonist, xanthine amine congener, totally inhibited adenosine-induced apoptosis. Furthermore, among more selective inhibitors of P(1) purinoceptor subtypes, only alloxazine, an antagonist of A(1)- and A(2)-adenosine receptors, completely inhibited adenosine-induced ASMC apoptosis, suggesting that adenosine triggers ASMC apoptosis via either 1 or both of these receptors. However, 8-cyclopentyl-1,3-dipropylxanthine, 8-(3-chlorostyryl) caffeine, and 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1, 4-(+/-)-dihydropyridine-3,5-dicarboxylate, which are A(1)-, A(2a)-, and A(3)-adenosine receptor antagonists, did not inhibit adenosine-induced apoptosis, suggesting an involvement of the A(2b)-receptor in this process. Moreover, the cAMP increase followed by cAMP-dependent protein kinase activation appears essential to mediate adenosine-induced ASMC apoptosis, thus confirming the previous hypothesis. These results indicate that adenosine-induced apoptosis of ASMCs is essentially mediated via A(2b)-adenosine receptor and involves a cAMP-dependent pathway.


Subject(s)
Adenosine/physiology , Apoptosis/physiology , Arteries/physiology , Extracellular Space/metabolism , Muscle, Smooth, Vascular/physiology , Receptors, Purinergic P1/physiology , Arteries/cytology , Arteries/metabolism , Cells, Cultured , Cyclic AMP/physiology , Humans , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Receptor, Adenosine A2B , Receptors, Purinergic P1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...